PTX Media related, page-1048

I think you have to listen to SYC's statements to appreciate the intonation. In fact, you'll probably get a chuckle like I did. Its at 24:05 onwards: https://prescienttherapeutics.investorportal.com.au/prescient-therapeutics-investor-replay-ptx100/

Its fair to say that he is speaking in terms of a general re-rate for the company over time which would naturally raise the SP / MCap as well as raise our profile in the industry and in the market. The reference he made to NEU's rerate following accelerated approval was in the previous webcast. I took it to mean that accelerated approval would be the catalyst that starts the ball rolling and with ongoing success from that point will bring about significant upside for SHs.

PTX100 can go into a Phase 2 trial with less than 100 cohorts straight to market if efficacy hits the benchmarks in that trial. It does involve what SYC referred to as a Post-Confirmatory Study but that is subsequent to the drug being approved for market. Had to laugh too at SYC saying, "We will be selling drug, baby!" We are talking about 3 yrs down the track, though, but it won't involve the lengthy 7 to 10 yr Phase 3 trial protocol which also costs massively more to run.